

(43) International Publication Date 7 March 2002 (07.03.2002)

PCT

(10) International Publication Number WO 02/018404 A3

Brian, William; 15 Vesta Avenue, St. Albans, Hert-

fordshire AL1 2PJ (GB). HOBBS, Christopher, John; 9 Magnolia Close, Hertford, Hertfordshire SG13 7UR

(GB). JIANG, Wen-Rong; 20 Salmon Close, Welwyn Garden City, Hertfordshire AL7 1TR (GB). MARTIN,

Joseph, Armstrong; 10 The Chownes, West Common. Harpenden, Herts AL5 2BN (GB). MERRETT, John,

Herbert; 23 Bush Spring, Baldock, Hertfordshire SG7 6QT (GB). NAJERA, Isabel; 49 Salisbury Avenue, St.

Albans, Hertfordshire AL1 4TZ (GB). SHIMMA, Nobuo; Higashikaigan-Minami 2-11-19, Chigasaki-shi, Kana-

gawa-ken 253-0054 (JP). TSUKUDA, Takuo; 540-22

C07H 19/06, (51) International Patent Classification7: 19/16, A61K 31/7064, 31/7076, A61P 31/14

(21) International Application Number: PCT/EP01/09633

(22) International Filing Date: 21 August 2001 (21.08.2001)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

30 August 2000 (30.08.2000) GB

0021285.2 0026611.4

31 October 2000 (31.10.2000)

(71) Applicant: F. HOFFMANN-LA ROCHE AG [CH/CH]; 124, Grenzacherstrasse, CH-4070 Basle (CH).

(74) Agent: RAUBER, Beat; 124 Grenzacherstrasse, CH-4070 Basle (CH).

Rensyoji, Odawara-shi, Kanagawa-ken 250-0865 (JP).

(72) Inventors: DEVOS, Rene; 4 Salmon Close, Welwyn Garden City, Hertfordshire AL7 1TR (GB). DYMOCK,

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

[Continued on next page]

(54) Title: NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C

Use of compounds of formula I

(57) Abstract: Use of compounds of formula (I), wherein R1 is hydrogen, hydroxy, alkyl, hydroxyalkyl, alkoxy, halogen, cyano, isocyano or azido; R² is hydrogen, hydroxy, alkoxy, chlorine, bromine or iodine; R3 is hydrogen; or R2 and R3 together represent =CH2; or R2 and R3 represent fluorine; X is O, s or CH2; a, b, c, d denoting asymmetric carbon atoms each of which is substituted with 4 different substituents; and B signifies a purine base B1 which is connected through the 9-nitrogen of formula (B1), wherein R4 is hydrogen, hydroxyl, alkyl, alkoxy, alkylthio, aryloxy, arylthio, heterocyclyl, NR7R8, halogen or SH; R5 is hydrogen, hydroxy, alkyl, haloalkyl, cycloalkyl, alkoxy, alkylthio, aryl, aryloxy, arylthio, heterocyclyl, heterocyclylamino, halogen, NR⁷R⁸, NHOR⁹, NHNR⁷R⁸ or SH; R⁶ is hydrogen, hydroxy, alkyl, alkoxy, alkylthio, aryloxy, arylthio, heterocyclyl, NR⁷R⁸, halogen, SH or cyano; R⁷ and R⁸ are independently of each other hydrogen, alkyl, aryl, hydroxyalkyl, alkenylalkyl, alkynylalkyl, cycloalkyl or acyl; R9 is hydrogen, alkyl or aryl; or B signifies an oxidised purine base B2 which is connected through the 9-nitrogen of formula (B2), wherein R4, R5 and R6 are as defined above; or B signifies a purine base B3 which is connected through the 9-nitrogen of formula (B3), wherein R4 and R6 are as defined above; R10 is hydrogen, alkyl or aryl; Y is O, S or NR11; R11 is hydrogen, hydroxy, alkyl, OR9, heterocyclyl or NR7R8; R7, R8 and R9 are as defined above; or B signifies a pyrimidine base B4 which is connected through the 1-nitrogen of formula (B4), wherein Z is O or S; R¹² is hydrogen, hydroxy, alkyl, alkoxy, haloalkyl, alkylthio, aryl, aryloxy, arylthio, heterocyclyl, heterocyclylamino, halogen, NR7R8, NHOR9, NHNR7R8 or SH; R13 is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, haloalkyl, cycloalkyl or halogen; R7, R8 and R9 are as defined above; or B signifies a pyrimidine base B5 which is connected through the 1-nitrogen of formula (B5), wherein Y, Z, R10 are as defined above for the treatment of diseases mediated by the Hepatitis C Virus (HIV) or for the preparation of a medicament for such treatment. The invention is concerned with novel and known purine and pyrimidine nucleoside derivatives, their use as inhibitors of subgenomic Hepatitis C Virus (HCV) RNA replication and pharmaceutical compositions of such compounds.





CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,

CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- (88) Date of publication of the international search report: 14 November 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

International Application No
PCT/EP 01/09633

CLASSIFICATION OF SUBJECT MATTER PC 7 CO7H19/06 CO7H A61K31/7064 A61K31/7076 A61P31/14 CO7H19/16 According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) IPC 7 CO7H A61K A61P Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ, CHEM ABS Data C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. 1,2,5,6, WO 94 01443 A (WELLCOME FOUND ; KOSZALKA X GEORGE WALTER (US); DRAANEN NANINE AGNETA) 20 January 1994 (1994-01-20) examples claims page 3, paragraph 3 X WO 98 16184 A (ICN PHARMACEUTICALS ; AVERTT 1,15,16 DEVERON (US); TAM ROBERT (US); WANG GU) 23 April 1998 (1998-04-23) examples claims page 11, line 14 Further documents are listed in the continuation of box C. Patent family members are listed in annex. Special categories of cited documents: "T" later document published after the international filling date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the *A* document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the International *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to Involve an inventive step when the document is taken alone document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docu-*O* document referring to an oral disclosure, use, exhibition or ments, such combination being obvious to a person skilled in the art. document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 5 July 2002 26. 07. 2002 Name and mailing address of the ISA Authorized officer European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 de Nooy, A

International application No. PCT/EP 01/09633

INTERNATIONAL SEARCH REPORT

Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This Inte	emational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
	Although claim 55 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound.
2. X	Claims Nos.: 43,49-57 (all partially) because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
	see FURTHER INFORMATION sheet PCT/ISA/210
з. 🔲	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This Inte	rnational Searching Authority found multiple inventions in this international application, as follows:
	see additional sheet
	As a result of the prior review under R. 40.2(e) PCT, no additional fees are to be refunded.
1. X	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
з	As only some of the required additional search fees were timely paid by the applicant, this international Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark	on Protest X The additional search fees were accompanied by the applicant's protest.
	No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 43,49-57 (all partially)

The initial phase of the search revealed a very large number of documents relevant to the issue of novelty for claim 43. So many documents were retrieved that it is impossible to determine which parts of the claim may be said to define subject-matter for which protection might legitimately be sought (Article 6 PCT). For these reasons, it appears impossible to execute a meaningful search and/or to issue a complete search report over the whole breadth of the claims. Consequently, the search and the report for this claim has been restricted to the case where R13'''' is an alkyl but not methyl.

Present claims 49-57 relate to an extremely large number of compounds. In fact, the claims contain so many options, that a lack of clarity (and/or conciseness) within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible. Consequently, the above mentioned claims have been searched insofar as the compounds of claim 49 fall within earlier compound claims.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1 (in part), 3-4 (in part), 12-13 (in part), 14, 34, 35, 50-56 (in part)

Compounds of Formula I-a of claim 34 where B' = B2-a of claim 34, and uses, compositions and processes pertaining thereto.

2. Claims: 1 (in part), 3-4 (in part), 15-16 (in part), 17, 36, 37, 50-56 (in part)

Compounds of Formula I-b of claim 36 where B' $^{\prime}$ = B3-a of claim 36, and uses, compositions and processes pertaining thereto.

3. Claims: 1-4 (in part), 18-25 (in part), 26, 27-28 (in part), 29, 38-42, 50-56 (in part)

Compounds of Formula I-c of claim 38 where B''' = B4-a of claim 38, compounds of Formula I-d of claim 40 where B''' = B4-b of claim 40 or 41, and uses, compositions and processes pertaining thereto.

4. Claims: 1-4 (in part), 30-32 (in part), 33, 43-48, 50-56 (in part)

Compounds of Formula I-e of claim 43 where B'''' = B5-a of claim 43, compounds of Formula I-f of claim 45 where B''''' = B5-b of claim 45, compounds of Formula I-g of claim 47 where B'''''' = B5-c of claim 47 and uses, compositions and processes pertaining thereto.

5. Claims: 1-4 (in part), 5-10, 12-13 (in part), 15-16 (in part), 18-25 (in part), 27-28 (in part), 30-32 (in part), 55-56 (in part)

Use of compounds of the above mentioned claims which do not fall within one of the previous subjects for the treatment of Hepatitis C Virus or for the preparation of a medicament for such treatment.

0./0	- DOCUMENTS CONCINCING TO THE THE TANK	101/21 01/09633
	in) DOCUMENTS CONSIDERED TO BE RELEVANT italion of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
х	WO 94 05687 A (UNIV BIRMINGHAM; WELLCOME FOUND (GB); MILLER JOHN ALLEN (GB); YOUN) 17 March 1994 (1994-03-17) examples claims	1,2, 30-32
A	page 4, line 22 - line 36 EP 0 468 352 A (NIPPON KAYAKU KK) 29 January 1992 (1992-01-29) examples claims page 14, line 17	1
х	US 5 102 873 A (MONTGOMERY JOHN A ET AL) 7 April 1992 (1992-04-07) example 3	34
x	US 4 755 594 A (BRIDGES ALEXANDER J ET AL) 5 July 1988 (1988-07-05) example 4	34
X	P.J.M. VAN GALEN ET AL.: "A binding site model and structure-activity relationships for the rat A3 adenosine receptor" MOLECULAR PHARMACOLOGY, vol. 45, 1994, pages 1101-1111, XP008000722 compound 30	34
А	US 5 998 387 A (SCAMMELLS PETER J ET AL) 7 December 1999 (1999-12-07) figure 2	34
A	K. MIURA ET AL.: "Chemical conversion of adenosine to guanosine (Nucleosides and nucleotides. XI)" CHEM. PHARM. BULL., vol. 23, 1975, pages 464-466, XP002190612 chart 1	34
x	W.M. HAMMARGREN ET AL.: "Identification of a novel nucleoside, 1,N6-dimethyladenosine, in human cancer urine" ANALYTICA CHIMICA ACTA, vol. 247, 1991, pages 201-209, XP008005307 compound 1	36
x	US 3 891 623 A (VORBRUGGEN HELMUT ET AL) 24 June 1975 (1975-06-24) examples 2,3	38

		PCI/EP 01/09633
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Calegory •	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	H. VORBRÜGGEN ET AL.: "Eine neue einfache Synthese von Cytidinen" LIEBIGS ANN. CHEM., 1975, pages 988-1002, XP002204034 compound 19	38
X	XX. ZHOU ET AL.: "Pyridyl groups for protection of the imide functions of uridine and guanosine. Exploration of their displacement reactions for site-specific modifications of uracil and guanine bases" ACTA CHEMICA SCANDINAVICA B, vol. 40, 1986, pages 806-816, XP002204035 the whole document	38
X	R.W. MILES ET AL.: "Nucleic acid related compounds. 87. Nucleophilic functionalization of cytidine and 2'-deoxycytidine derivatives via elaboration of the 4-amino group into a readily displaced 1,2,4-triazol-4-yl substituent" J. ORG. CHEM., vol. 60, 1995, pages 7066-7069, XP002204036 compounds 3,4	38
x	G.E. KEYSER ET AL.: "Iodomethylethers from 1,3-dioxolane and 1,3-oxothiolane: preparation of acyclic nucleoside analogs" TETRAHEDRON LETTERS, 1979, pages 3263-3264, XP002204037 compound 3	38
x	US 4 526 988 A (HERTEL LARRY W) 2 July 1985 (1985-07-02) the whole document	40
X	HERTEL L W: "SYNTHESIS OF 2-DEOXY-2,2-DIFLUORO-D-RIBOSE AND 2-DEOXY-2,2-DIFLUORO-D-RIBOFURANOSYL NUCLEOSIDES" JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 53, no. 11, 27 May 1988 (1988-05-27), pages 2406-2409, XP000572745 ISSN: 0022-3263 the whole document -/	40

		PC1/EP 01/09633
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHOU T S ET AL: "STEREOSPECIFIC SYNTHESIS OF 2-DEOXY-2,2-DIFLUORORIBONOLACTONE AND ITS USE IN THE PREPARATION OF 2'-DEOXY-2'.2'-DIFLUORO-BETA-D-RIBOFURANOS YL PYRIMIDINE NUCLEOSIDES: THE KEY ROLE OF SELECTIVE CRYSTALLIZATION" SYNTHESIS, GEORG THIEME VERLAG. STUTTGART, DE, no. 6, 1 June 1992 (1992-06-01), pages 565-570, XP000572747 ISSN: 0039-7881 compounds 1,16	40
X	KOTRA L P ET AL: "STRUCTURE-ACTIVITY RELATIONSHIPS OF 2'-DEOXY-2',2'-DIFLUORO-L-ERYTHRO-PENTOFURANOSYL NUCLEOSIDES" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 40, no. 22, 1997, pages 3635-3644, XP000867642 ISSN: 0022-2623 compounds 43-52	40
X	KOTRA L P ET AL: "Synthesis of 2,3-dideoxy-2,2-difluoro-1-glycero-pentofu ranosyl nucleosides" CARBOHYDRATE RESEARCH, ELSEVIER SCIENTIFIC PUBLISHING COMPANY. AMSTERDAM, NL, vol. 306, no. 1-2, January 1998 (1998-01), pages 69-80, XP004204788 ISSN: 0008-6215 scheme 1	40
X	M. SEKINE, T. NAKANISHI: "Facile synthesis of 3'-O-methylthymidine and 3'-deoxythymidine and related deoxygenated thymidine derivative: A new method for selective deoxygenation of secondary hydroxy groups" J. ORG. CHEM., vol. 55, 1990, pages 924-928, XP002204038 compound 2	43
X .	A. HAMPTON ET AL.: "Species- or Isozyme-specific enzyme inhibitors. 5. Differential effects of thymidine substituents on affinity for rat thymidine kinase isozymes" J. MED. CHEM., vol. 25, 1982, pages 644-649, XP002204039 compounds 7d,e	43
	-/	

CICantin	DOCUMENTS CONCIDENCE TO BE DELEVIANT	PCT/EP 01/09633
C.(Continua Category °	ation) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Julio Hora	Online of Societies and Control and Control of the relevant passages	nelevalu to dain 140.
X	S. EL-KOUSY ET AL.: "Synthesis and investigation of antiviral activity of 3'-0-(aminoalkyl)-thymidines and their quarternary ammonium salts" MONATSHEFTE FÜR CHEMIE, vol. 125, 1994, pages 713-721, XP002204040 compounds 4a-d, 6a-d	43
X	N.K. KOCHETKOV ET AL.: "The mechanism of the reaction of hydroxylamine and O-methylhydroxylamine with cytidine" TETRAHEDRON LETTERS, 1967, pages 3253-3257, XP002204041 compound 4a	47,48
E	WO 01 90121 A (NOVIRIO PHARMACEUTICALS LTD; UNI DEGLI STUDI DI CAGLIARI (IT); LAC) 29 November 2001 (2001-11-29) the whole document	1-57
	•	
	·	

					PCT	
	tent document in search report		Publication date		Patent family member(s)	Publication date
WO	9401443	Α	20-01-1994	AU	4508593 A	31-01-1994
				CA	2139132 A1	20-01-1994
				CN	1087089 A	25-05-1994
				EP	0648218 A1	19-04-1995
				WO	9401443 A1	20-01-1994
				JP	7508531 T	21-09-1995
				MX	9303985 A1	28-02-1994
				ZA	9304742 A	03-01-1995
WO	9816184	Α	23-04-1998	ΑÜ	727177 B2	07-12-2000
				ΑU	4899997 A	11-05-1998
				BR	9714349 A	14-11-2000
				CA	2322053 A1	16-07-1998
				CA	2323791 A1	23-04-1998
				CN	1286258 A	07-03-2001
				CN	1296011 A	23-05-2001
				CN	1233254 A	27-10-1999
				CZ	9901267 A3	14-07-1999
				EP	1072607 A2	31-01-2001
				EP	0961775 A2	08-12-1999
				HU	0001186 A2	28-05-2001
				JP	2001524936 T	04-12-2001
				JP	2002105096 A	10-04-2002
				NO	991784 A	15-06-1999
				NO	20004326 A	15-06-1999
				NO	20004328 A	15-06-1999
				NZ	505531 A	31-08-2001
				NZ	505553 A	30-11-2001
				NZ	505554 A	30-11-2001
				PL	332694 A1	27-09-1999
				SĪ	20024 A	29-02-2000
				SK	48199 A3	18-01-2000
				US	2002058635 A1	16-05-2002
				WO	9816184 A2	23-04-1998
				AU	736075 B2	26-07-2001
				AU	6023898 A	03-08-1998
				BR	9807473 A	21-03-2000
				CN	1312254 A	12-09-2001
				CN	1289594 A	04-04-2001
				CN	1253504 T	17-05-2000
				EP	1103559 A1	30-05-2001
				EP	0998293 A1	10-05-2001
				HU	0001526 A2	28-05-2001
				JP	2002515892 T	28-05-2001
				JP	2002515692 T 2002080490 A	19-03-2002
				NO	993439 A	13-09-1999
				NO	20004327 A	13-09-1999
				NO	20004327 A 20004329 A	13-09-1999
				NU PL	336579 A1	03-07-2000
			•			
	•					
				MO	9830223 A1	16-07-1998
۳U 	9405687	Δ	17-03-1994	All	4973393 A	29-03-1994
NO	5 400001	•	2, 00 2007			
				MO	9405687 A1	17-03-1994
					2 MP LL 2 L2 (3 / ML)	11: U.J ~ 77 +
 WO	9405687	A	17-03-1994	SI SK	9820003 A 94099 A3	30-06-1999 11-06-2001

D.44.do	- 1	D. March .			01/09633
Patent document cited in search report		Publication date		Patent family member(s)	Publication date
EP 0468352	A	29-01-1992	AU	642031 B2	07-10-1993
			AU	8125391 A	30-01-1992
			CA	2047644 A1	25-01-1992
			CN	1059524 A ,B	18-03-1992
			EP	0468352 A2	29-01-1992
			JP	5001044 A	08-01-1993
			US	5374625 A	20-12-1994
US 5102873	A	07-04-1992	NONE		
US 4755594	Α	05-07-1988	AU	592728 B2	18-01-1990
			AU	6797287 A	06-08-1987
			CA	1270821 A1	26-06-1990
			DK	46687 A	01-08-1987
			EP	0232813 A2	19-08-1987
	•		FI	870371 A	01-08-1987
		•	KR	9100602 B1	28-01-1991
			NO	870390 A ,B,	03-08-1987
			NZ	219128 A	29-01-1990
			PH	23342 A	14-07-1989
			PT JP	84226 A ,B 62228095 A	01 - 02-1987 06-10-1987
			ZA	8700120 A	31-08-1988
US 5998387		07-12-1999	US	5736528 A	07-04-1998
00 033000/	А	0/-17-1223	US	5631260 A	20-05-1997
			US	5446046 A	29-08-1995
			AU	728439 B2	11-01-2001
			AU	1522097 A	28-07-1997
			BR	9612324 A	28-12-1999
			CA	2238736 A1	10-07-1997
			EP	1019426 A1	19-07-2000
			JP	2000502712 T	07-03-2000
			NZ	326608 A	28-04-2000
			NZ	502628 A	29-06-2001
			WO	9724363 A1	10-07-1997
			บร	5668139 A	16-09-1997
			AT	187726 T	15-01-2000
			AU	699630 B2	10-12-1998
			AU	1044995 A	22-05-1995
		•	CA	2172726 A1	04-05-1995
			DE	69422191 D1	20-01-2000 25-05-2000
			DE DK	69422191 T2 725782 T3	13-06-2000
			EP	0725782 A1	14-08-1996
			ES	2141913 T3	01-04-2000
			GR	3032730 T3	30-06-2000
			JP	9507052 T	15-07-1997
			JP	2002105094 A	10-04-2002
			PT	725782 T	31-05-2000
			WO	9511904 A1	04-05-1995
	A	24-06-1975	DE	2122991 A1	16-11-1972
US 3891623	••		BE	783026 A1	06-11-1972
US 3891623					15-09-1976
US 3891623			CH	5/9585 A5	13-03-13/0
US 3891623			CH CS	579585 A5 171723 B2	
US 3891623			CH CS FR	171723 B2 2135249 A5	29-10-1976 15-12-1972

	ent document in search report		Publication date		Patent family member(s)	Publication date
US	3891623	A		NL	7206058 A	07-11-1972
US	4526988	Α	02-07-1985	AT	29726 T	15-10-1987
				AU	565856 B2	01-10-1987
				AU	2537484 A	13-09-1984
				BG	40814 A3	16-02-1987
				CA	1218647 A1	03-03-1987
				CA	1223869 C	07-07-1987
				CS	246075 B2	16-10-1986
				CY	1489 A	08-12-1989
				DD	216468 A5	1212-1984
				DE	3466224 D1	22-10-1987
				DK	114484 A ,B,	11-09-1984
				DK	190590 A	10-08-1990
				EP	0122707 A1	24-10-1984
				ĒS	530364 D0	01-12-1985
				FI	840890 A ,B,	11-09-1984
		•		· GB	2136425 A ,B	19-09-1984
				GB	2172287 A ,B	17-09-1986
				GR	81845 A1	12-12-1984
				HK	44989 A	09-06-1989
				HU	193893 B	28-12-1987
				IE	57071 B1	22-04-1992
				ĪĹ	71143 A	31-07-1988
				IL	80463 A	31-07-1988
				JP	1986188 C	08-11-1995
				JP	6009602 A	18-01-1994
				JP	6102655 B	14-12-1994
				JP	1833350 C	29-03-1994
				JP	5042438 B	28-06-1993
				JP	59175498 A	04-10-1984
		*		KE	3874 A	30-06-1989
				KR	8601283 B1	05-09-1986
				LU	88791 A9	05-11-1996
				MX	9203246 A1	31-07-1992
				NZ	207358 A	06-03-1987
				PH	23240 A	06-06-1989
				PH	23593 A	11-09-1989
				PL	246601 A1	13-08-1985
				PT	78181 A ,B	01-04-1984
				RO	89963 A1	30-09-1986
				SG	21889 G	14-07-1989
				SU	1442076 A3	30-11-1988
				US	4808614 A	28-02-1989
				US	5015743 A	14-05-1991
				US	5118820 A	02-06-1992
				บร	4692434 A	08-09-1987
				ZA	8401605 A	30-10-1985
WO C	0190121	Α	29-11-2001	AU	7490601 A	03-12-2001
				WO	0190121 A2	29-11-2001